USPTO Examiner CRAIG KAILA ANGELIQUE - Art Unit 1618

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18776861PEPTIDE-UREA DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND APPLICATION THEREOFJuly 2024June 2025Allow1121YesNo
18770529RADIOPHARMACEUTICAL COMPOSITION AND METHODSJuly 2024February 2025Allow711NoNo
18070994Temporary Wrinkle SoftenerNovember 2022February 2025Abandon2630YesNo
17981502TOOTHPASTE CAPSULENovember 2022April 2024Abandon1810NoNo
17976631COMPOSITIONS AND METHODS FOR IMPROVING THE APPEARANCE OF SKINOctober 2022August 2025Abandon3440YesNo
17962471BIOBASED POLYGLYCERYL ESTERS AND COMPOSITIONS COMPRISING THE SAMEOctober 2022September 2025Allow3540YesNo
17951747Combination therapy for the treatment or prevention of neurological disordersSeptember 2022January 2026Abandon4001NoNo
17944620Jammed Emulsion Toothpaste CompositionsSeptember 2022June 2025Allow3340NoYes
17891450COMPOSITIONS AND METHODS FOR THE TREATMENT OF RHEUMATOID ARTHRITISAugust 2022December 2025Abandon4001NoNo
17732631COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASESApril 2022October 2025Abandon4211NoNo
17595709SURFACTANT MICROBUBBLES COMPOSITIONS AND PROCESS FOR PREPARING THEREOFNovember 2021May 2024Allow3010NoNo
17612953METHODS AND COMPOSITIONS FOR INHIBITING GAPDHNovember 2021August 2024Abandon3310NoNo
17612988LESION DETECTION METHODNovember 2021October 2025Abandon4711NoNo
176121233,5-BIS(PHENYL)-1H-HETEROARYL DERIVATIVES AS MEDICAMENTSNovember 2021April 2025Abandon4130NoNo
17594991FORMULATIONS OF PSMA IMAGING AGENTSNovember 2021March 2026Abandon5221NoNo
17604703NOVEL RADIOLABELLED COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCEROctober 2021July 2025Allow4511NoNo
17502010MICROBUBBLE DISPERSION SYSTEM STABILIZED WITH POLYDOPAMINE NANOPARTICLES FOR HIGHLY-EFFICIENT INTRAVENOUS OXYGEN SUPPLY AND METHOD FOR PREPARING THE SAMEOctober 2021February 2025Allow4010NoNo
17594356RADIOLABELLED TRACERS FOR PDE1 DETECTION AND THERAPYOctober 2021March 2026Abandon5321NoNo
17602966AMPK/CASPASE-6 AXIS CONTROLS LIVER DAMAGE IN NONALCOHOLIC STEATOHEPATITISOctober 2021March 2026Abandon5340NoNo
17450264COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOFOctober 2021May 2025Abandon4311NoNo
17488810COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHYSeptember 2021July 2024Allow3320NoNo
17598929HIGH-AFFINITY CU(I) LIGANDS AND METHODS OF USE THEREOFSeptember 2021January 2026Allow5231NoNo
17598620TARGETED SYNERGISTIC CANCER IMMUNOTHERAPYSeptember 2021March 2026Abandon5321NoNo
17439161Stimuli-Responsive Compositions, Imaging Systems, and Methods for Using the Same for Biomedical ApplicationsSeptember 2021October 2025Abandon4921NoNo
17437380COMPOSITION FOR MEASURING MEDICATION COMPLIANCE AND METHOD THEREOFSeptember 2021February 2025Abandon4101NoNo
17272444Cyclic PeptideSeptember 2021October 2025Abandon5521NoNo
17467412NANOPARTICLES WITH TUNABLE AFTERGLOW AND COMPOSITIONS AND METHODS THEREOFSeptember 2021January 2026Allow5331NoNo
17310759COMBINATION OF AR ANTAGONISTS AND TARGETED THORIUM CONJUGATESAugust 2021June 2024Abandon3410NoNo
17432733COMPOSITIONS AND METHODS FOR RADIOTHERAPY USING CHELATED RADIOTHERAPEUTIC AGENTS AND NON-TARGET TISSUE BLOCKADEAugust 2021September 2025Abandon4921NoYes
17432039HIPK INHIBITORS AND METHODS OF USE THEREOFAugust 2021January 2025Abandon4101NoNo
17402092ANALYTE-SENSITIVE PROBES AND CONTACT LENS FOR DIAGNOSIS OF OCULAR PATHOLOGIESAugust 2021September 2024Abandon3710NoNo
17310604Targeted Radiopharmaceutical for Tumor and Its Use in the Imaging-guided Combination Therapy of Targeted Radiotherapy and ImmunotherapyAugust 2021March 2025Allow4320NoNo
17430263NEUROTRANSMITTER-BASED BRAIN MAPPING METHOD AND USE OF BRAIN MAPAugust 2021December 2024Abandon4001NoNo
17428831Methods and Compositions for Clinical Evaluation of Therapeutic AgentsAugust 2021July 2025Abandon4821NoNo
17428732TREATMENT EFFICIENCY EVALUATIONAugust 2021July 2025Abandon4720NoNo
17426962PSMA BINDING DUAL MODE RADIOTRACER AND THERAPEUTICJuly 2021March 2025Allow4411NoNo
17427006CANCER DIAGNOSTIC IMAGING AGENTSJuly 2021May 2025Allow4621YesNo
17387258Transition Metal Macrocyclics as MRI Contrast Agents for Molecular ImagingJuly 2021June 2024Abandon3420NoNo
17424973NON-HUMAN ANIMAL MODELS OF SÉZARY SYNDROMEJuly 2021October 2024Abandon3901NoNo
17423526Compound Targeting Norepinephrine TransporterJuly 2021March 2025Allow4421YesNo
17422211GRAPHENE QUANTUM DOTS-GADOLINIUM ION CHELATE AS MAGNETIC RESONANCE IMAGING CONTRAST AGENT AND PREPARATION METHOD THEREOFJuly 2021December 2024Allow4111YesNo
17421995COMPOSITION FOR TARGETING MEDULLARY THYROID CANCERJuly 2021January 2025Abandon4301NoNo
17421239MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 4July 2021November 2024Abandon4001NoNo
17420671RADIOTHERAPEUTIC COMBINATION THERAPY FOR THE TREATMENT OF CANCERJuly 2021November 2024Abandon4010NoNo
17420666MOLECULAR RENAL PROBES FOR DETECTING ACUTE KIDNEY INJURYJuly 2021January 2025Allow4211NoNo
17365134IMAGING COMPOSITION COMPRISING POROUS SILICON MICRO-PARTICLESJuly 2021August 2025Allow5040NoNo
17420218Prediction and/or Determination Marker for Effectiveness of Treatment with Drug Containing PD-1 Signal InhibitorJuly 2021March 2025Abandon4520NoNo
17419649MAGNETIC RESONANCE IMAGING DRUG CONTAINING A DEUTERATED NATURAL BRANCHED-CHAIN AMINO ACID, AND DIAGNOSTIC METHOD USING SAID DRUGJune 2021June 2025Abandon4721NoNo
17419381Methods for Treating Cancer Using Combinations of PARP Inhibitors and Antibody RadioconjugatesJune 2021February 2025Abandon4320NoNo
17417989RADIODRUG FOR DIAGNOSTIC/THERAPEUTIC USE IN NUCLEAR MEDICINE AND RADIO-GUIDED MEDICINEJune 2021July 2025Abandon4920NoNo
17418142NANOPARTICLE, CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING COMPRISING SAME AND ZWITTERIONIC LIGAND COMPOUNDJune 2021September 2025Abandon5021NoNo
17312949RADIOACTIVE I-LABELED LAROTRECTINIB COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOFJune 2021July 2024Allow3701YesNo
17413061METHODS FOR TREATING CANCERJune 2021February 2026Abandon5630NoYes
17342608THERAPEUTIC CONJUGATESJune 2021July 2025Abandon5030NoNo
17298944TUMOR TARGETING VITAMIN B12 DERIVATIVES FOR X-RAY ACTIVATED CHEMOTHERAPYJune 2021November 2025Abandon5340NoNo
17327551PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULINGMay 2021December 2024Allow4320NoNo
17294500Antibodies Conjugated With Actinium-225 and Actinium-227, and Related Compositions and MethodsMay 2021September 2025Abandon5230NoNo
17294187BENZAZEPIN-L,7-DIOL-DERIVED RADIOLABELED LIGANDS WITH HIGH IN VIVO NMDA SPECIFICITYMay 2021May 2025Abandon4820NoNo
17293455RADIOLABELED BOMBESIN-DERIVED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERSMay 2021September 2024Abandon4010NoNo
17291851A SERIES OF CATALYSTS FOR THE HYPERPOLARISATION OF SUBSTRATESMay 2021October 2025Abandon5330NoNo
17286006METHOD FOR CALCULATING TOLERANCE DOSE OF HUMAN BODY TO SUGAR ALCOHOL AND FUNCTIONAL SUGARApril 2021December 2025Abandon5731NoNo
17285775Phospholipid-Free Small Unilamellar Vesicles (PFSUVS) for Drug DeliveryApril 2021May 2025Abandon4930NoNo
17283761Hybrid Tracers for Targeted Cancer Imaging and TreatmentApril 2021May 2025Allow5030NoNo
17176123CEST-MRI Methods for Detection of DiseasesFebruary 2021October 2024Abandon4401NoNo
17267175BINDNG MOLECULES TO TUMOR ASSOCIATED MACROPHAGES AND METHODS OF USEFebruary 2021June 2025Abandon5220NoYes
17052275BACTERIOPHAGE-BASED SERS-ACTIVE GOLD NANOHALO STRUCTURE AND MANUFACTURING METHOD THEREFORFebruary 2021September 2024Abandon4620NoNo
17266383Separation of RadiometalsFebruary 2021July 2024Abandon4101NoNo
17057624A Drug For Treating Disorders Of An Organ Or Tissue Function And Diseases Accompanied By Such Disorders, And The Method For Obtaining It.November 2020June 2025Abandon5521YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CRAIG, KAILA ANGELIQUE.

Strategic Value of Filing an Appeal

Total Appeal Filings
3
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
3
(100.0%)
Filing Benefit Percentile
0.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner CRAIG, KAILA ANGELIQUE - Prosecution Strategy Guide

Executive Summary

Examiner CRAIG, KAILA ANGELIQUE works in Art Unit 1618 and has examined 58 patent applications in our dataset. With an allowance rate of 27.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.

Allowance Patterns

Examiner CRAIG, KAILA ANGELIQUE's allowance rate of 27.6% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CRAIG, KAILA ANGELIQUE receive 1.74 office actions before reaching final disposition. This places the examiner in the 37% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CRAIG, KAILA ANGELIQUE is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +57.4% benefit to allowance rate for applications examined by CRAIG, KAILA ANGELIQUE. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 20.6% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 13.3% of cases where such amendments are filed. This entry rate is in the 14% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Petition Practice

When applicants file petitions regarding this examiner's actions, 80.0% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.